What Дюфастон Treats: Main Uses and Benefits

The primary therapeutic role of Dydrogesterone is to manage various clinical conditions and symptoms related to an underlying deficiency in the female hormone progesterone. It provides supportive relief and plays a role in managing symptoms related to temporary physiological imbalance across relevant therapeutic domains. Dydrogesterone is indicated for a wide range of conditions associated with progesterone deficiencies.

Relief from Menstrual Irregularity and Pain

This medication is commonly used to help with symptoms arising from menstrual irregularity, including secondary amenorrhea and dysfunctional uterine bleeding. It is relevant for easing symptoms related to inflammatory or irritative states, such as the chronic pain of endometriosis and severe dysmenorrhea. This general benefit may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic periods.

Support for Early Pregnancy and Fertility

Dydrogesterone is considered relevant in clinical scenarios where additional symptomatic support is needed in the context of pregnancy and fertility. It is commonly used in situations involving threatened miscarriage and for women with a history of recurrent pregnancy loss. Furthermore, it generally supports the patient during Assisted Reproductive Technology (ART) cycles by assisting with symptoms related to functional stress. This supportive relief may assist with maintaining functional stability when symptoms are more noticeable, contributing to easing the overall symptom load.

---

Quick Fact: Symptom Support and Functional Stability
Symptom Cluster: Cyclical pain (dysmenorrhea, pelvic pain) and abnormal bleeding patterns.
Patient Benefit: Contributes to easing the overall symptom load and is applied in addressing the symptoms of irregular cycles.

Regulatory References

1. FDA Verification Portal

Eligibility Map: Who can and cannot use Dydrogesterone

This eligibility profile is based strictly on the absolute prohibitions and patient status restrictions defined in official government regulatory documents.

Classification	Population or Condition
Absolute Contraindication	Known hypersensitivity to Dydrogesterone or excipients [Source 1.2]
Absolute Contraindication	Known or suspected sex hormone-dependent malignant tumours (e.g., meningioma) [Source 1.2]
Absolute Contraindication	Undiagnosed vaginal bleeding (until cause is established) [Source 1.2]
Absolute Contraindication	Severe hepatic disease until liver function normalizes [Source 1.2]

Age and Development Status

• Not Recommended: The safety and efficacy profile has not been established for use in adolescents aged 12 to 18 years [Source 4.1].
• No Relevant Use: The medicine is not indicated for the pediatric population before menarche (first menstruation) [Source 4.1].
• Allowed Population: Primarily intended for adult women (reproductive age and postmenopausal, the latter typically for Hormone Replacement Therapy in combination with oestrogen) [Source 5.1].

Conditional Use and Status Restrictions

• Pregnancy: May be administered when there is a clear, official indication (such as threatened or habitual miscarriage) [Source 3.2].
• Lactation: Use is not recommended while breastfeeding, as progestogens and their metabolites may be excreted in breast milk [Source 3.2].
• Organ Function: Use requires caution and close monitoring in patients with a history of or current abnormal liver function that is not classified as severe [Source 2.1].
• Comorbidities: Caution is also advised for patients with a history of depression or porphyria, as these conditions may be influenced by sex hormones [Source 1.5, 2.1].

This structure reflects how regulatory documents define the eligible population by establishing clear prohibitions and conditions related to underlying clinical states, malignancy risk, and developmental or physiological status.

Interactions with other medicines and products

Pharmacokinetic Interactions (Metabolism)

The systemic clearance of Dydrogesterone is primarily dependent on metabolic pathways involving the Cytochrome P450 (CYP) 3A4 enzyme. Co-administration with strong CYP3A4 inducers results in a pharmacokinetic interaction that significantly alters Dydrogesterone's exposure.

Strong enzyme inducers accelerate the metabolism of Dydrogesterone, leading to a reduction in systemic plasma concentrations (exposure), which may diminish the therapeutic effect. Documented inducers include certain anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine), anti-infectives (e.g., rifampicin, rifabutin), and the herbal preparation St. John's Wort (Hypericum perforatum). Conversely, co-administration with strong CYP3A4 inhibitors may decrease clearance and potentially increase plasma concentrations.

Pharmacodynamic and Co-therapy Constraints

A pharmacodynamic interaction is noted regarding blood coagulation: Dydrogesterone may reduce the effectiveness of co-administered anticoagulant medicines. Additionally, when Dydrogesterone is used in combined therapy with an oestrogen, the combination is subject to the contraindications and precautions formally specified in the regulatory label for the oestrogen product.

Specific Agonism of the Progesterone Receptor

This mechanism centers on Dydrogesterone acting as a highly selective agonist of the Progesterone Receptor (PR), engaging both its PR-A and PR-B isoforms. This specificity is defined by its negligible binding affinity for non-target steroid receptors, including the Androgen Receptor, Estrogen Receptor, and Glucocorticoid Receptor. This direct molecular interaction initiates gene transcription, which is the essential step for mediating subsequent physiological effects.

Endometrial Transformation and Stability

The activation of the PR complex triggers a crucial cellular cascade within the uterine lining. This process converts the estrogen-primed endometrium from a proliferative state to a secretory and decidualized state. This mechanism modifies the tissue structure and biochemical environment of the endometrium, which results in the decidualization and structural conditioning of the uterine lining.

️ Uterine Muscle Modulation and Systemic Constraint

The drug influences uterine smooth muscle activity, leading to the modulation and inhibition of myometrial hypermotility. Its mechanistic constraint is the lack of significant central anti-gonadotropic activity, meaning it avoids suppression of the Luteinizing Hormone (LH) surge, thereby preserving the hormonal signals for the ovarian cycle.

Official Administration Guidelines for Dydrogesterone

Дюфастон (Dydrogesterone) is administered based on established protocols. These instructions govern the route, dosing, and proper timing, ensuring standardized use across different treatment areas.

---

Feature	Official Instruction
Route of Administration	The medicine is for oral use (taken by mouth).
Dosage Form and Handling	Supplied as a 10 mg film-coated tablet. The tablet has a score line intended only to facilitate swallowing and is not to be used for dividing the dose.
Dose Distribution Rule	Total daily doses of 20 mg or 30 mg must be divided into smaller amounts and taken evenly distributed throughout the day to ensure consistent levels.
Frequency and Schedule	Treatment follows specific patterns: Cyclic (e.g., 10 mg to 20 mg daily for a set number of days within the menstrual cycle, such as Day 11 to Day 25) or Continuous (e.g., 30 mg daily for Assisted Reproductive Technology (ART) support, continuing up to 10 weeks if pregnancy is confirmed).
Missed Dose Protocol	If a dose is missed by more than 12 hours from the scheduled time, the forgotten tablet is to be skipped. The patient should continue with the next dose at the regular time.
Population Rule	The safety and efficacy of dydrogesterone in adolescents aged 12 to 18 years have not been established, and no dosing recommendation can be made for this age group.

---

This structured instruction set defines the procedural requirements for administering Dydrogesterone, detailing the oral route, the rule for divided daily dosing at higher amounts, and the protocol for managing missed tablets. Use involves adhering to cyclic or time-bound schedules to manage treatment duration as specified in prescribing information.

Research Evidence / Overview of Studies for Дюфастон

---

Evidence for Studies Supporting Pregnancy Outcomes

Research has focused on the use of Dydrogesterone in studies involving pregnant women experiencing early bleeding (threatened miscarriage) or those with a history of recurrent pregnancy loss (RPL). The primary outcomes measured in these studies included the live birth rate and the rate of pregnancy continuation. Studies reported various measurements of these outcomes, but analyses noted variation in the findings, suggesting inconsistency in the research. The evidence level for these specific research scenarios remains moderate, and follow-up durations were typically limited, meaning data on potential long-term maternal or neonatal outcomes are not a central feature of the published reports.

---

Evidence for Studies Addressing Menstrual and Hormonal Irregularity

Research has explored the use of this medicine in conditions like secondary amenorrhea (absence of periods) and irregular bleeding patterns. For secondary amenorrhea, placebo-controlled trials included women with normal estrogen levels and measured the occurrence of withdrawal bleeding and subsequent cycle regularity. Studies report generally similar measurements of withdrawal bleeding in this population, and the evidence level for this specific scenario is high. However, the certainty is lower for irregular bleeding patterns because most evidence for this application is derived from observational studies, which typically face greater methodological limitations than randomized controlled trials.

---

Evidence for Studies in Chronic Pain Conditions (Endometriosis)

Studies evaluated the use of this medicine in women diagnosed with endometriosis, a condition characterized by fluctuating symptoms. Research examined outcomes related to physical discomfort by using standardized rating scales, focusing on symptoms like chronic pelvic pain and painful periods (dysmenorrhea). The available evidence for endometriosis is generally described as low certainty. This is due to the findings being mixed, the use of studies with modest sample sizes, and the high variability in patient populations.

---

What is Still Uncertain About Dydrogesterone Research

A major limitation is that follow-up durations were limited in many key studies, meaning long-term effects on the durability of any observed response are not fully established. Data for certain groups, such as women with specific comorbidities or those with the most severe forms of conditions, remain insufficient. Evidence quality varies across applications, with reliance on observational reports in areas like irregular bleeding, meaning certainty remains low in these specific areas.

Key Studies & References

1. Clinical Practice Guideline on Miscarriage (Summary of evidence on progestogens)

Common questions about Дюфастон (FAQ)

---

Q: Is Dydrogesterone considered safe to take during pregnancy?

Regulatory documents describe Dydrogesterone for specific conditional use in pregnancy, such as managing threatened or habitual miscarriage in cases of progesterone deficiency. Regulatory documents indicate that the administration of the drug for these conditions follows specific protocols and schedules.

Q: What is the main difference between Dydrogesterone and Utrogestan (Micronized Progesterone)?

Dydrogesterone is a synthetic progestogen classified as a retro-steroid, giving it a unique molecular structure. This structure is described as enabling high oral bioavailability (efficient absorption when taken by mouth) and highly selective activity on the progesterone receptor, features that distinguish it from micronized progesterone.

Q: How quickly does Dydrogesterone start working?

Pharmacokinetic studies reported in official documents focus on the time required to reach the maximum plasma concentration of the active substance. This time is generally stated to be within a general range, typically less than three hours after a dose is taken by mouth.

Q: How long after stopping Dydrogesterone should a period start?

According to official product information, when Dydrogesterone is used to treat conditions like dysfunctional uterine bleeding, a withdrawal bleed is typically expected to occur a few days after the final dose of the treatment course is completed.

Q: How long can Dydrogesterone be taken?

The permitted duration of use is determined by the specific medical condition being addressed, as outlined in the official protocols. For example, use may be noted for at least three consecutive cycles for certain infertility treatments or may continue up to 20 weeks of pregnancy for habitual miscarriage support.

Q: Is it true that Dydrogesterone is used to prevent miscarriage?

Regulatory documents indicate that Dydrogesterone is listed for the treatment of threatened miscarriage and habitual miscarriage (recurrent pregnancy loss) associated with confirmed progesterone deficiency.

Q: What is dydrogesterone and how is it related to progesterone?

Dydrogesterone is a synthetic progestogen and a structural derivative known as a retro-steroid. It is closely related to the natural hormone progesterone and functions by selectively activating the progesterone receptors in the body.

Q: Can I stop taking Dydrogesterone on my own?

Official information highlights specific conditions, such as the diagnosis of a meningioma or the onset of a new migraine-type headache, that require immediate medical review and potential discontinuation by a healthcare professional. Any change to the treatment plan requires professional oversight.

Q: Can Dydrogesterone affect blood test results?

Studies on the active substance and its primary metabolite have investigated this topic. Official research has determined that Dydrogesterone does not indicate any relevant analytical interference with the commonly used progesterone immunoassays (blood tests).

Q: Does Dydrogesterone affect pregnancy test results?

Research has examined the drug's effect on key markers used in first-trimester screening tests for chromosomal anomalies. The findings indicated no statistically significant difference in the measured screening markers between patients using the drug and control groups.

Q: What are the general expectations from Dydrogesterone treatment?

The therapeutic goals, as described in regulatory information, include the correction of progesterone deficiency and the regulation of menstrual cycles. Additionally, for conditions like endometriosis, the expected outcome includes the relief of associated symptoms such as painful periods and pelvic pain.

Q: In what dosages is Dydrogesterone usually available?

The product is typically supplied in the pharmaceutical form of a 10 mg film-coated tablet containing dydrogesterone as the sole active ingredient.

Q: Are there age restrictions for taking Dydrogesterone?

Official documents state that the safety and effectiveness have not been established for use in adolescents aged 12 to 18 years. Furthermore, the drug has no relevant use for the pediatric population before the onset of the first menstruation (menarche).

Q: Can Dydrogesterone be the cause of headaches?

Headache is listed in regulatory documents as a Common adverse reaction. This classification means it is reported to affect a significant number of users, as noted in the safety documentation.

Q: What is 'breakthrough bleeding' when taking Dydrogesterone?

Official documentation notes that breakthrough bleeding or spotting may occur, especially during the first months of treatment. Official documentation recommends seeking medical review if this bleeding continues, starts after some time, or persists after treatment stops.

Q: Does Dydrogesterone affect libido?

Effects on libido are not generally listed as common adverse reactions in the official safety information. The safety profile is based on classifications established by regulatory authorities.

Q: What components, besides the active substance, are in Dydrogesterone tablets?

In addition to the active substance Dydrogesterone, the tablets contain several excipients (inactive ingredients) that form the tablet structure. These may include common substances such as lactose monohydrate, hypromellose, maize starch, colloidal anhydrous silica, and magnesium stearate.

Q: Can Dydrogesterone help with endometriosis?

Endometriosis is listed in official regulatory documents as a therapeutic indication for Dydrogesterone. The objective of the treatment is to provide relief from associated symptoms, such as chronic pelvic pain and painful periods.

Q: Is there information on how Dydrogesterone affects drivers?

Official documents note that Dydrogesterone may have a slight effect on the ability to drive or operate machinery. The official documentation notes that caution is recommended because in rare cases it may cause somnolence and/or dizziness, particularly during the first few hours after taking a dose.

Q: What precautions are described in official documents?

Official precautions define conditions that require close supervision and evaluation by a physician during treatment. These include a personal history of depression, a metabolic disorder called porphyria, and a current or historical issue with abnormal liver function.

Q: Can Dydrogesterone cause allergic reactions?

Hypersensitivity to the active substance or excipients is listed as an absolute contraindication. Furthermore, allergic skin reactions are listed as uncommon side effects, and Angioedema (a serious form of swelling) is listed as a rare side effect in official safety information.

Storage and Disposal Requirements for Duphaston

The storage of Duphaston (dydrogesterone) tablets is defined by regulatory authorities to ensure product stability and safety. The official labeled conditions must be strictly followed:

Storage Scope	Official Regulatory Requirement
Temperature Limit	Do not store above 30 C and do not freeze.
Packaging	Keep the tablets in their original container/packaging.
Child Safety	Must be kept out of the sight and reach of children.
Shelf Life	Do not use the tablets after the printed expiry date.

Official Disposal Instructions

To prevent environmental contamination, unused or expired Duphaston must not be thrown away with household rubbish or into wastewater. Disposal must be carried out in accordance with local regulations; patients are instructed to return old or unused medicine to a pharmacist or doctor for safe handling and destruction. These rules ensure the product is stored securely and discarded appropriately.